Auxo Firm Directory · Independent Research Profile

Welsh Carson Anderson Stowe

Welsh Carson Anderson Stowe, commonly known as WCAS, is a private equity firm focused exclusively on Healthcare and Technology. Its public materials describe partnerships with management teams and founders, operational improvement, internal growth initiatives, and strategic acquisitions.

Key takeaway

What stands out about Welsh Carson Anderson Stowe

WCAS publicly identifies Healthcare and Technology as its exclusive sectors and describes a partnership-oriented investment approach that includes operational improvements, internal growth initiatives, and strategic acquisitions. Its official Our Firm page does not publish a universal transaction-size, equity-check, enterprise-value, revenue, or EBITDA threshold.[1][2][6][8][9][10][11]

What does Welsh Carson Anderson Stowe invest in?

Welsh Carson Anderson Stowe, commonly branded WCAS, is a private equity firm focused on Healthcare and Technology. WCAS states that it partners with management teams and founders and seeks to create value through operational improvements, internal growth initiatives, and strategic acquisitions.

WCAS states that it has raised over $31 billion across 14 funds and has over 190 current or former portfolio companies. Its 2024 Responsible Investment Report states $33 billion of capital, approximately 100 people, 200+ portfolio companies, and 60%+ repeat management teams.[1][2][6]

WCAS describes a value-creation approach centered on operational improvements, internal growth initiatives, and strategic acquisitions. Its public materials also describe partnerships with management teams and founders and identify growth-oriented operators prepared to make acquisitions and strategic decisions and refine their service or experience.[1][2]

Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.

Public size / criteria information
WCAS states that it has raised over $31 billion across 14 funds and has over 190 current or former portfolio companies. Its 2024 Responsible Investment Report states $33 billion of capital, approximately 100 people, 200+ portfolio companies, and 60%+ repeat management teams. The cited official Our Firm page does not publish a universal minimum or maximum transaction size, minimum equity check, target enterprise-value range, or revenue or EBITDA threshold.[1][6]

What should a business owner evaluate before considering a transaction with Welsh Carson Anderson Stowe?

Owners evaluating WCAS can clarify how the firm’s stated management-partnership model, operational-improvement resources, internal-growth initiatives, and strategic-acquisition approach would apply to the proposed transaction. They can also request transaction-specific information on control, governance, retained ownership, management participation, acquisition plans, financing, investment horizon, and exit approach.

Because the cited official Our Firm page does not publish a universal transaction-size or financial-threshold mandate, owners should confirm the applicable equity check, enterprise-value range, revenue or EBITDA criteria, and transaction structure for the opportunity under consideration.[1][2]

01

What are WCAS’s current minimum and maximum equity checks and target enterprise-value ranges for this opportunity

The cited official Our Firm page does not publish a universal transaction-size range, minimum equity check, or target enterprise-value range.[1]
02

Would the proposed transaction involve majority control, a minority investment, or another partnership structure

WCAS’s public record includes a stated partnership model and a publicly announced majority investment, but the applicable structure must be confirmed for the proposed transaction.[1][8]
03

What rollover-equity, governance, management-retention, and liquidity expectations would apply

WCAS states that it partners with management teams and founders; the specific ownership and governance terms for a proposed transaction are not established by the cited materials.[1]

What companies does Welsh Carson Anderson Stowe target?

WCAS states that it partners with management teams and founders and looks for growth-oriented operators prepared to make acquisitions and strategic decisions and refine their service or experience.

The cited official Our Firm page does not publish a universal minimum or maximum transaction size, minimum equity check, target enterprise-value range, or revenue or EBITDA threshold. Specific company-level criteria should therefore be confirmed for the proposed transaction.[1]

WCAS states that it focuses exclusively on Healthcare and Technology. Its Healthcare areas include Care Delivery, Healthcare Information Technology, Pharma Value Chain, and Payor Services & Risk-Based Care. Its Technology portfolio page categorizes investments across B2B Software, FinTech, and Data & Information Services, among other technology areas.[3][4][5]

WCAS identifies itself in official transaction materials as a U.S. private equity firm and lists offices in New York and San Francisco. The sources cited for this profile do not establish a formal geographic investment mandate.[1]

WCAS’s public materials describe strategic acquisitions as part of its value-creation approach. They also identify portfolio-company acquisition activity: WCAS announced that portfolio company ImageTrend acquired biospatial and FlowMSP in a transaction announced February 19, 2025.

The cited materials establish both firm-level strategic-acquisition activity and portfolio-company acquisition activity, but do not establish a universal platform-versus-add-on policy.[2][9]

WCAS’s official Investments page lists companies including Absorb, AIA Contract Documents, AssistRx, Avetta, Clearwater Analytics, EquiLend, GovCIO, ImageTrend, Select Medical, Shields, Simeio, and TrueCommerce.

Its sector portfolio pages also identify Healthcare companies such as Abzena, Concentra, EnableComp, Norstella, and United Musculoskeletal Partners, and Technology companies such as LINQ and Quickbase, among others.[2][5][7]

WCAS announced a majority investment in AIA Contract Documents on July 8, 2025, alongside The American Institute of Architects and existing investor True Wind Capital. WCAS also announced that portfolio company ImageTrend acquired biospatial and FlowMSP in a transaction announced February 19, 2025.

WCAS announced completion of its majority acquisition of EquiLend on September 5, 2024. On April 2, 2024, WCAS announced that EQT Private Equity had agreed to acquire Avetta from WCAS.

The cited official announcements for these transactions do not disclose transaction consideration or valuation for the respective transactions.[8][9][10][11]

What is not clear from Welsh Carson Anderson Stowe's public investment criteria?

The cited official Our Firm page does not publish a universal minimum or maximum transaction size, minimum equity check, target enterprise-value range, or revenue or EBITDA threshold.

The cited official AIA Contract Documents, ImageTrend, EquiLend, and Avetta announcements do not disclose transaction consideration or valuation for those transactions.[1][8][9][10][11]

Questions to ask when evaluating Welsh Carson Anderson Stowe as a buyer or investment partner

What are WCAS’s current minimum and maximum equity checks and target enterprise-value ranges for this opportunity?
The cited official Our Firm page does not publish a universal transaction-size range, minimum equity check, or target enterprise-value range.[1]
Would the proposed transaction involve majority control, a minority investment, or another partnership structure?
WCAS’s public record includes a stated partnership model and a publicly announced majority investment, but the applicable structure must be confirmed for the proposed transaction.[1][8]
What rollover-equity, governance, management-retention, and liquidity expectations would apply?
WCAS states that it partners with management teams and founders; the specific ownership and governance terms for a proposed transaction are not established by the cited materials.[1]
Which operating resources would be assigned to the company, and how would internal growth and operational-improvement initiatives be defined?
WCAS states that it seeks to create value through operational improvements and internal growth initiatives, but the cited materials do not specify the resources or plan for an individual transaction.[2]
What strategic-acquisition and integration plans are contemplated for the company?
WCAS identifies strategic acquisitions as part of its value-creation approach and has announced portfolio-company acquisition activity, making the proposed acquisition plan a transaction-specific diligence topic.[2][9]
What is the expected investment horizon and exit approach for this transaction?
The cited materials describe WCAS’s investment activities and transactions but do not establish an expected investment horizon or exit approach for the proposed transaction.[1][2][10][11]

Sources & research notes

Public-source research
  1. Official website / firm overview
  2. Investment strategy
  3. Industry / market focus
  4. Industry / market focus
  5. Industry / market focus
  6. Transaction size / criteria
  7. Transaction / portfolio evidence
  8. Transaction / portfolio evidence
  9. Transaction / portfolio evidence
  10. Transaction / portfolio evidence
  11. Transaction / portfolio evidence
Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.